RNAZ (STOCKS)
TransCode Therapeutics, Inc. Common Stock
$8.570000
+0.170000 (+2.02%)
Prev close: $8.400000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Philippe P. Calais
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8.07M
- Employees
- 7
- P/E (TTM)
- -0.04
- P/B (TTM)
- 4.80
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$10.09M |
| Operating Expenses | $17.05M |
| Research and Development | $11.58M |
| Other Operating Expenses | $5.46M |
| Operating Income/Loss | -$17.05M |
| Income/Loss From Continuing Operations After Tax | -$27.13M |
| Income/Loss From Continuing Operations Before Tax | -$27.13M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$27.13M |
| Net Income/Loss Attributable To Noncontrolling Interest | $45.03K |
| Net Income/Loss Attributable To Parent | -$27.18M |
| Net Income/Loss Available To Common Stockholders, Basic | -$27.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$14.43K |
| Preferred Stock Dividends And Other Adjustments | -$14.43K |
| Basic Earnings Per Share | $1.06K |
| Diluted Earnings Per Share | $1.06K |
| Basic Average Shares | 6,837,073 |
| Diluted Average Shares | 6,837,073 |
| Assets | $5.23M |
| Current Assets | $4.75M |
| Prepaid Expenses | $18.15K |
| Other Current Assets | $4.73M |
| Noncurrent Assets | $475.63K |
| Fixed Assets | $19.91K |
| Other Non-current Assets | $455.73K |
| Liabilities | $3.80M |
| Current Liabilities | $2.97M |
| Noncurrent Liabilities | $832.88K |
| Equity | $1.43M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.43M |
| Liabilities And Equity | $5.23M |
| Net Cash Flow From Operating Activities | -$14.52M |
| Net Cash Flow From Operating Activities, Continuing | -$14.52M |
| Net Cash Flow From Investing Activities | $2.97M |
| Net Cash Flow From Investing Activities, Continuing | $2.97M |
| Net Cash Flow From Financing Activities | $15.48M |
| Net Cash Flow From Financing Activities, Continuing | $15.48M |
| Net Cash Flow | $3.94M |
| Net Cash Flow, Continuing | $3.94M |
| Comprehensive Income/Loss | -$27.13M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$27.13M |
| Other Comprehensive Income/Loss | $0.00 |